Sophia Genetics SA
$ 5.00
0.81%
05 Jun - close price
- Market Cap 358,952,000 USD
- Current Price $ 5.00
- High / Low $ 5.06 / 4.83
- Stock P/E N/A
- Book Value 0.64
- EPS -1.18
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -1.23 %
- 52 Week High 5.70
- 52 Week Low 2.59
About
Sophia Genetics SA (SOPH) is a pioneering company at the forefront of data-driven medicine, focusing on enhancing patient outcomes through advanced genomic and clinical data analytics. Utilizing cutting-edge machine learning technologies, the firm provides a comprehensive platform that enables healthcare providers to interpret complex genomic data, facilitating tailored treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with prominent healthcare organizations, Sophia Genetics is committed to transforming the landscape of precision medicine, solidifying its position as a leading entity in the genomics industry.
Analyst Target Price
$8.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-03 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.19 | -0.1707 | -0.2 | -0.25 | -0.18 | -0.1199 | -0.21 | -0.15 | -0.14 | -0.37 | -0.14 | -0.25 |
| Estimated EPS | -0.24 | -0.22 | -0.2 | -0.17 | -0.19 | -0.15 | -0.18 | -0.2 | -0.21 | -0.27 | -0.24 | -0.26 |
| Surprise | 0.05 | 0.0493 | 0 | -0.08 | 0.01 | 0.0301 | -0.03 | 0.05 | 0.07 | -0.1 | 0.1 | 0.01 |
| Surprise Percentage | 20.8333% | 22.4091% | 0% | -47.0588% | 5.2632% | 20.0667% | -16.6667% | 25% | 33.3333% | -37.037% | 41.6667% | 3.8462% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SOPH
2026-06-05 20:10:43
SOPHiA GENETICS SA's Chief Financial Officer, George Cardoza, purchased 20,000 Ordinary Shares at $4.95 each in an open-market transaction, increasing his direct holdings to 311,458 shares. This insider purchase, valued at $99,000, occurred during an open trading window and is highlighted as a positive signal for the company. The Form 4 filing details the transaction and Cardoza's updated beneficial ownership.
2026-06-05 01:09:36
BTIG has reiterated a Buy rating and an $8.00 price target on Sophia Genetics SA (NASDAQ:SOPH) after the company reported strong first-quarter revenue growth of 22%, surpassing analyst estimates. This growth was driven by increased volumes and the addition of 18 new customers, bringing their core genomics customer count to 537. The firm anticipates an inflection point in Sophia Genetics' revenue and margins due to a recovery in biopharma and more clinical customers adopting their applications.
2026-06-04 12:39:44
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) have signed a Memorandum of Understanding (MOU) to explore a joint venture focused on establishing a precision oncology hub. This collaboration aims to combine MSK's extensive clinical data with SOPHiA GENETICS' Ai-driven SOPHiA DDM™ platform to accelerate the discovery, development, and deployment of next-generation precision oncology solutions globally. The proposed hub will also provide infrastructure for biopharma companion diagnostics and clinical algorithms, although the specific terms of the strategic initiative are still being finalized.
2026-06-01 13:10:38
SOPHiA GENETICS (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the company's stock for $24,750 on May 26th, under a pre-arranged Rule 10b5-1 trading plan. This latest sale is part of frequent selling activity by Menu in recent months, though he still directly owns 250,780 shares valued at approximately $1.24 million. The company recently reported a wider-than-expected quarterly loss but revenue that beat estimates, with analysts currently rating the stock a "Hold" with a consensus price target of $7.50.
2026-06-01 11:10:38
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS (SOPH), sold 5,000 Ordinary Shares on May 26, 2026, at a weighted average price of $4.9548 per share. This transaction was part of a pre-arranged Rule 10b5-1(c) trading plan. Following the sale, Menu still holds a substantial 250,780 Ordinary Shares, indicating a portfolio adjustment rather than a major shift in his equity position.
2026-05-27 17:39:50
SOPHiA GENETICS (SOPH) reported Q1 2026 revenue of US$21.7 million, up from Q1 2025, but continues to face significant net losses, reaching US$80.9 million on a trailing 12-month basis. Despite revenue growth and bullish arguments about recurring high-value contracts, the company's valuation at 4.4x P/S is seen as high given persistent losses and no profitability expected within three years, raising concerns for investors and analysts alike. The steady quarterly losses around US$19 million despite increasing revenue suggest that efficiency gains have not yet translated into reduced absolute losses.
